BBIO vs. BSX

Last updated Jun 4, 2026

BBIO (BridgeBio Pharma, Inc.) and BSX (Boston Scientific Corporation) are both stocks. Both are in the Healthcare sector — BBIO in Biotechnology, BSX in Medical Devices. Over the past 5 years, BBIO returned 2.47%/yr vs 2.56%/yr for BSX. At a 0.20 correlation, their price movements are largely independent.

Performance

BBIO vs. BSX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in BridgeBio Pharma, Inc. (BBIO) and Boston Scientific Corporation (BSX). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, BBIO achieves a -14.39% return, which is significantly higher than BSX's -49.98% return.

BBIO

• 1D: 2.50%
• 1M: -5.09%
• YTD: -14.39%
• 6M: -11.69%
• 1Y: 74.52%
• 3Y*: 66.21%
• 5Y*: 2.47%
• 10Y*: —

BSX

• 1D: 0.02%
• 1M: -16.11%
• YTD: -49.98%
• 6M: -51.62%
• 1Y: -53.74%
• 3Y*: -2.73%
• 5Y*: 2.56%
• 10Y*: 7.66%

*Multi-year figures are annualized to reflect compound growth (CAGR)

BBIO vs. BSX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019
BBIO BridgeBio Pharma, Inc.	-14.39%	178.75%	-32.03%	429.79%	-54.32%	-76.54%	102.88%	27.22%
BSX Boston Scientific Corporation	-49.98%	6.75%	54.51%	24.94%	8.92%	18.16%	-20.50%	7.85%

Correlation

The correlation between BBIO and BSX is 0.07, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.07
Correlation (3Y) Calculated over the trailing 3-year period	0.14
Correlation (5Y) Calculated over the trailing 5-year period	0.19
Correlation (All Time) Calculated using the full available price history since Jun 28, 2019	0.20

The correlation between BBIO and BSX shifts across timeframes, from 0.07 (1 year) to 0.20 (all time), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap BBIO : $12.75B BSX : $71.30B
EPS BBIO : -$3.76 BSX : $2.38
PS Ratio BBIO : 22.36 BSX : 3.46
Total Revenue (TTM) BBIO : $566.04M BSX : $20.62B
Gross Profit (TTM) BBIO : $538.20M BSX : $14.52B
EBITDA (TTM) BBIO : -$602.24M BSX : $4.76B

Return for Risk

BBIO vs. BSX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BBIO

BBIO Risk / Return Rank: 82
BBIO Sharpe Ratio Rank: 83
BBIO Sortino Ratio Rank: 79
BBIO Omega Ratio Rank: 79
BBIO Calmar Ratio Rank: 86
BBIO Martin Ratio Rank: 86

BSX

BSX Risk / Return Rank: 1
BSX Sharpe Ratio Rank: 0
BSX Sortino Ratio Rank: 1
BSX Omega Ratio Rank: 1
BSX Calmar Ratio Rank: 3
BSX Martin Ratio Rank: 0

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BBIO vs. BSX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for BridgeBio Pharma, Inc. (BBIO) and Boston Scientific Corporation (BSX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	BBIO	BSX	Difference
Sharpe ratio Return per unit of total volatility	1.61	-1.56	+3.16
Sortino ratio Return per unit of downside risk	2.26	-2.37	+4.63
Omega ratio Gain probability vs. loss probability	1.30	0.65	+0.65
Calmar ratio Return relative to maximum drawdown	3.70	-0.96	+4.66
Martin ratio Return relative to average drawdown	9.47	-2.19	+11.66
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

BBIO vs. BSX - Sharpe Ratio Comparison

The current BBIO Sharpe Ratio is 1.61, which is higher than the BSX Sharpe Ratio of -1.56. The chart below compares the historical Sharpe Ratios of BBIO and BSX, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	BBIO	BSX	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.61	-1.56	+3.16
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.03	0.10	-0.07
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.28	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.16	0.19	-0.04

Drawdowns

BBIO vs. BSX - Drawdown Comparison

The maximum BBIO drawdown since its inception was -92.80%, roughly equal to the maximum BSX drawdown of -89.15%. Use the drawdown chart below to compare losses from any high point for BBIO and BSX.

Drawdown Indicators

	BBIO	BSX	Difference
Max Drawdown Largest peak-to-trough decline	-92.80%	-89.15%	-3.65%
Max Drawdown (1Y) Largest decline over 1 year	-20.25%	-55.91%	+35.66%
Max Drawdown (3Y) Largest decline over 3 years	-49.08%	-55.91%	+6.83%
Max Drawdown (5Y) Largest decline over 5 years	-91.89%	-55.91%	-35.98%
Max Drawdown (10Y) Largest decline over 10 years	—	-55.91%	—
Current Drawdown Current decline from peak	-18.06%	-55.90%	+37.84%
Average Drawdown Average peak-to-trough decline	-45.85%	-38.75%	-7.10%
Ulcer Index Depth and duration of drawdowns from previous peaks	7.89%	24.56%	-16.67%

Volatility

BBIO vs. BSX - Volatility Comparison

The current volatility for BridgeBio Pharma, Inc. (BBIO) is 11.77%, while Boston Scientific Corporation (BSX) has a volatility of 16.20%. This indicates that BBIO experiences smaller price fluctuations and is considered to be less risky than BSX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	BBIO	BSX	Difference
Volatility (1M) Calculated over the trailing 1-month period	11.77%	16.20%	-4.43%
Volatility (6M) Calculated over the trailing 6-month period	34.50%	32.82%	+1.68%
Volatility (1Y) Calculated over the trailing 1-year period	46.93%	34.63%	+12.30%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	86.00%	25.66%	+60.34%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	83.86%	27.29%	+56.57%

Dividends

BBIO vs. BSX - Dividend Comparison

Neither BBIO nor BSX has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

BBIO vs. BSX - Profitability Comparison

The chart below illustrates the profitability comparison between BridgeBio Pharma, Inc. and Boston Scientific Corporation over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

BBIO - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, BridgeBio Pharma, Inc. reported a gross profit of 178.39M and revenue of 180.60M. Therefore, the gross margin over that period was 98.8%.

BSX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Boston Scientific Corporation reported a gross profit of 3.61B and revenue of 5.20B. Therefore, the gross margin over that period was 69.4%.

BBIO - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, BridgeBio Pharma, Inc. reported an operating income of -105.96M and revenue of 180.60M, resulting in an operating margin of -58.7%.

BSX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Boston Scientific Corporation reported an operating income of 1.07B and revenue of 5.20B, resulting in an operating margin of 20.6%.

BBIO - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, BridgeBio Pharma, Inc. reported a net income of -164.04M and revenue of 180.60M, resulting in a net margin of -90.8%.

BSX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Boston Scientific Corporation reported a net income of 1.34B and revenue of 5.20B, resulting in a net margin of 25.7%.

Frequently Asked Questions

Can I hold both BBIO and BSX in my portfolio?

BBIO and BSX have a correlation of 0.07, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, BBIO or BSX?

BSX has higher volatility (16.20%) compared to BBIO (11.77%). In terms of maximum drawdown, BBIO dropped -92.80% vs BSX's -89.15%.

Which has better risk-adjusted returns?

BBIO currently has the higher Sharpe Ratio (1.61 vs -1.56), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.